Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Smruthi Karthikeyan; Joshua I Levy; Peter De Hoff; Greg Humphrey; Amanda Birmingham; Kristen Jepsen; Sawyer Farmer; Helena M. Tubb; Tommy Valles; Caitlin E Tribelhorn; Rebecca Tsai; Stefan Aigner; Shashank Sathe; Niema Moshiri; Benjamin Henson; Abbas Hakim; Nathan A Baer; Tom Barber; Pedro Belda-Ferre; Marisol Chacon; Willi Cheung; Evelyn S Crescini; Emily R Eisner; Alma L Lastrella; Elijah S Lawrence; Clarisse A Marotz; Toan T Ngo; Tyler Ostrander; Ashley Plascencia; Rodolfo A Salido; Phoebe Seaver; Elizabeth W Smoot; Daniel McDonald; Robert M Neuhard; Angela L Scioscia; Alysson M. Satterlund; Elizabeth H Simmons; Dismas B. Abelman; David Brenner; Judith Carbone Bruner; Anne Buckley; Michael Ellison; Jeffrey Gattas; Steven L Gonias; Matt Hale; Faith Kirkham Hawkins; Lydia Ikeda; Hemlata Jhaveri; Ted Johnson; Vince Kellen; Brendan Kremer; Gary C. Matthews; Ronald McLawhon; Pierre Ouillet; Daniel Park; Allorah Pradenas; Sharon Reed; Lindsay Riggs; Alison M. Sanders; Bradley Sollenberger; Angela Song; Benjamin White; Terri Winbush; Christine M Aceves; Catelyn Anderson; Karthik Gangavarapu; Emory Hufbauer; Ezra Kurzban; Justin Lee; Nathaniel L Matteson; Edyth Parker; Sarah A Perkins; Karthik S Ramesh; Refugio Robles-Sikisaka; Madison A Schwab; Emily Spencer; Shirlee Wohl; Laura Nicholson; Ian H Mchardy; David P Dimmock; Charlotte A Hobbs; Omid Bakhtar; Aaron Harding; Art Mendoza; Alexandre Bolze; David Becker; Elizabeth T Cirulli; Magnus Isaksson; Kelly M Schiabor Barrett; Nicole L Washington; John D Malone; Ashleigh Murphy Schafer; Nikos Gurfield; Sarah Stous; Rebecca Fielding-Miller; Tommi Gaines; Richard Garfein; Cheryl A. M. Anderson; Natasha K. Martin; Robert T Schooley; Brett Austin; Duncan R. MacCannell; Stephen F Kingsmore; William Lee; Seema Shah; Eric McDonald; Alexander T. Yu; Mark Zeller; Kathleen M Fisch; Christopher A. Longhurst; Patty Maysent; David Pride; Pradeep K. Khosla; Louise C Laurent; Gene W Yeo; Kristian G Andersen; Rob Knight.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21268143

RESUMO

As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at scale, especially in areas with limited resources, participation, or testing/sequencing capacity, which can also introduce biases. SARS-CoV-2 RNA concentration in wastewater successfully tracks regional infection dynamics and provides less biased abundance estimates than clinical testing. Tracking virus genomic sequences in wastewater would improve community prevalence estimates and detect emerging variants. However, two factors limit wastewater-based genomic surveillance: low-quality sequence data and inability to estimate relative lineage abundance in mixed samples. Here, we resolve these critical issues to perform a high-resolution, 295-day wastewater and clinical sequencing effort, in the controlled environment of a large university campus and the broader context of the surrounding county. We develop and deploy improved virus concentration protocols and deconvolution software that fully resolve multiple virus strains from wastewater. We detect emerging variants of concern up to 14 days earlier in wastewater samples, and identify multiple instances of virus spread not captured by clinical genomic surveillance. Our study provides a scalable solution for wastewater genomic surveillance that allows early detection of SARS-CoV-2 variants and identification of cryptic transmission.

2.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21267101

RESUMO

Monitoring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on surfaces is emerging as an important tool for identifying past exposure to individuals shedding viral RNA. Our past work has demonstrated that SARS-CoV-2 reverse transcription-quantitative PCR (RT-qPCR) signals from surfaces can identify when infected individuals have touched surfaces such as Halloween candy, and when they have been present in hospital rooms or schools. However, the sensitivity and specificity of surface sampling as a method for detecting the presence of a SARS-CoV-2 positive individual, as well as guidance about where to sample, has not been established. To address these questions, and to test whether our past observations linking SARS-CoV-2 abundance to Rothia spp. in hospitals also hold in a residential setting, we performed detailed spatial sampling of three isolation housing units, assessing each sample for SARS-CoV-2 abundance by RT-qPCR, linking the results to 16S rRNA gene amplicon sequences to assess the bacterial community at each location and to the Cq value of the contemporaneous clinical test. Our results show that the highest SARS-CoV-2 load in this setting is on touched surfaces such as light switches and faucets, but detectable signal is present in many non-touched surfaces that may be more relevant in settings such as schools where mask wearing is enforced. As in past studies, the bacterial community predicts which samples are positive for SARS-CoV-2, with Rothia sp. showing a positive association. ImportanceSurface sampling for detecting SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is increasingly being used to locate infected individuals. We tested which indoor surfaces had high versus low viral loads by collecting 381 samples from three residential units where infected individuals resided, and interpreted the results in terms of whether SARS-CoV-2 was likely transmitted directly (e.g. touching a light switch) or indirectly (e.g. by droplets or aerosols settling). We found highest loads where the subject touched the surface directly, although enough virus was detected on indirectly contacted surfaces to make such locations useful for sampling (e.g. in schools, where students do not touch the light switches and also wear masks so they have no opportunity to touch their face and then the object). We also documented links between the bacteria present in a sample and the SARS-CoV-2 virus, consistent with earlier studies.

3.
Sydney C Morgan; Stefan Aigner; Catelyn Anderson; Pedro Belda-Ferre; Peter De Hoff; Clarisse A Marotz; Shashank Sathe; Mark Zeller; Noorsher Ahmed; Xaver Audhya; Nathan A Baer; Tom Barber; Bethany Barrick; Lakshmi Batachari; Maryann Betty; Steven M Blue; Brent Brainard; Tyler Buckley; Jamie Case; Anelizze Castro-Martinez; Marisol Chacon; Willi Cheung; LaVonnye Chong; Nicole G Coufal; Evelyn S Crescini; Scott DeGrand; David P Dimmock; J Joelle Donofrio-Odmann; Emily R Eisner; Mehrbod Estaki; Lizbeth Franco Vargas; Michele Freddock; Robert M Gallant; Andrea Galmozzi; Nina J Gao; Sheldon Gilmer; Edyta M Grzelak; Abbas Hakim; Jonathan Hart; Charlotte Hobbs; Greg Humphrey; Nadja Ilkenhans; Marni Jacobs; Christopher A Kahn; Bhavika K Kapadia; Matthew Kim; Sunil Kurian; Alma L Lastrella; Elijah S Lawrence; Kari Lee; Qishan Liang; Hanna Liliom; Valentina Lo Sardo; Robert Logan; Michal Machnicki; Celestine G Magallanes; Clarence K Mah; Denise Malacki; Ryan J Marina; Christopher Marsh; Natasha K Martin; Nathaniel L Matteson; Daniel J Maunder; Kyle McBride; Bryan McDonald; Daniel McDonald; Michelle McGraw; Audra R Meadows; Michelle Meyer; Amber L Morey; Jasmine R Mueller; Toan T Ngo; Julie Nguyen; Viet Nguyen; Laura J Nicholson; Alhakam Nouri; Victoria Nudell; Eugenio Nunez; Kyle O'Neill; R Tyler Ostrander; Priyadarshini Pantham; Samuel S Park; David Picone; Ashley Plascencia; Isaraphorn Pratumchai; Michael Quigley; Michelle Franc Ragsac; Andrew C Richardson; Refugio Robles-Sikisaka; Christopher A Ruiz; Justin Ryan; Lisa Sacco; Sharada Saraf; Phoebe Seaver; Leigh Sewall; Elizabeth W Smoot; Kathleen M Sweeney; Chandana Tekkatte; Rebecca Tsai; Holly Valentine; Shawn Walsh; August Williams; Min Yi Wu; Bing Xia; Brian Yee; Jason Z Zhang; Kristian G Andersen; Lauge Farnaes; Rob Knight; Gene W Yeo; Louise C Laurent.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21257885

RESUMO

BackgroundSuccessful containment strategies for SARS-CoV-2, the causative virus of the COVID-19 pandemic, have involved widespread population testing that identifies infections early and enables rapid contact tracing. In this study, we developed a rapid and inexpensive RT- qPCR testing pipeline for population-level SARS-CoV-2 detection, and used this pipeline to establish a clinical laboratory dedicated to COVID-19 testing at the University of California San Diego (UCSD) with a processing capacity of 6,000 samples per day and next-day result turnaround times. Methods and findingsUsing this pipeline, we screened 6,786 healthcare workers and first responders, and 21,220 students, faculty, and staff from UCSD. Additionally, we screened 6,031 preschool-grade 12 students and staff from public and private schools across San Diego County that remained fully or partially open for in-person teaching during the pandemic. Between April 17, 2020 and February 5, 2021, participants provided 161,582 nasal swabs that were tested for the presence of SARS-CoV-2. Overall, 752 positive tests were obtained, yielding a test positivity rate of 0.47%. While the presence of symptoms was significantly correlated with higher viral load, most of the COVID-19 positive participants who participated in symptom surveys were asymptomatic at the time of testing. The positivity rate among preschool-grade 12 schools that remained open for in-person teaching was similar to the positivity rate at UCSD and lower than that of San Diego County, with the children in private schools being less likely to test positive than the adults at these schools. ConclusionsMost schools across the United States have been closed for in-person learning for much of the 2020-2021 school year, and their safe reopening is a national priority. However, as there are no vaccines against SARS-CoV-2 currently available to the majority of school-aged children, the traditional strategies of mandatory masking, physical distancing, and repeated viral testing of students and staff remain key components of risk mitigation in these settings. The data presented here suggest that the safety measures and repeated testing actions taken by participating healthcare and educational facilities were effective in preventing outbreaks, and that a similar combination of risk-mitigation strategies and repeated testing may be successfully adopted by other healthcare and educational systems.

4.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21251159

RESUMO

As of January of 2021, the highly transmissible B.1.1.7 variant of SARS-CoV-2, which was first identified in the United Kingdom (U.K.), has gained a strong foothold across the world. Because of the sudden and rapid rise of B.1.1.7, we investigated the prevalence and growth dynamics of this variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission. We found that the RT-qPCR testing anomaly of S gene target failure (SGTF), first observed in the U.K., was a reliable proxy for B.1.1.7 detection. We sequenced 212 B.1.1.7 SARS-CoV-2 genomes collected from testing facilities in the U.S. from December 2020 to January 2021. We found that while the fraction of B.1.1.7 among SGTF samples varied by state, detection of the variant increased at a logistic rate similar to those observed elsewhere, with a doubling rate of a little over a week and an increased transmission rate of 35-45%. By performing time-aware Bayesian phylodynamic analyses, we revealed several independent introductions of B.1.1.7 into the U.S. as early as late November 2020, with onward community transmission enabling the variant to spread to at least 30 states as of January 2021. Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...